VIVUS, Inc (NASDAQ:VVUS) is a biopharmaceutical company which makes medicines for sleep disorder, obesity and diabetes. The company’s shares declined considerably after performing well in the last couple of days. Aspen Investment Fund LLC may make an offer to take over the drug maker, which is VVUS has stated in their regulatory filing with the SEC. However, looking at the filing done by the VVUS, there are certain points which need to be examined closely. VIVUS, Inc. (NASDAQ:VVUS) weekly performance is 6.90%. On last trading day company shares ended up $5.27. Analysts mean target price for the company is $6.00. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average is 2.00%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), the discoverer of the BELVIQ® drug, announced initiating the dosage of a pivotal Phase 1b clinical trial of its novel APD334 drug. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell -2.44% in last trading session and ended the day on $6.00. ARNA Gross Margin is 93.70% and its return on assets is -8.10%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is -15.73%.
June 01, 2014 Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced, for the first time, data from its Phase 2 trial of Iclusig® (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) in last trading session was closed at $6.69, while trading in range of $6.61-$6.74. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date performance is -1.91%.
MannKind Corporation (NASDAQ:MNKD) is anticipating the approval of its diabetes treatment drug – Afrezza, by July 15, 2014! FDA’s advisory committee earlier recommended the use of this drug to treat Type1 and Type2 Diabetes. However, the regulatory authority delayed its Prescription Drug User Fee Act or PDUFA review by July 15. MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $10.28. Company weekly volatility is calculated as 7.76% and price to cash ratio as 111.59. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 15.51%.
Gilead Sciences Inc. (NASDAQ:GILD) is a well known pharmaceutical company in all over the world. Recently news made its way in top headlines according to which GILD is way too expensive when it comes to drug manufacturing. According to US insurers group,” GILD often delivers goods that are way too expensive for normal people. The main reason behind the unreasonable pricing of Gilead Sciences Inc. (NASDAQ:GILD) is but the intention of taking advantage of available opportunities in the insurance sector of United States of America.”The insurers accused GILD of delivering such high priced drugs and said that the company wanted to make money through unreasonable pricing. According to a survey done in United States of America recently, the total cost of treatment of Hepatitis C named Sovaldi, which was taken from GILD, came around $84,000, the highest in last few years. Gilead Sciences, Inc. (NASDAQ:GILD) net profit margin is 33.50% and weekly performance is 1.45%. On last trading day company shares ended up $82.39. Analysts mean target price for the company is $100.57. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average is 8.07%.
Leave a Reply